10-Q: WEED, Inc. Reports Continued Losses, Focus on Restructuring

WEED, Inc. filed its quarterly report for the period ending June 30, 2026, detailing ongoing operational losses, a significant accumulated deficit, and a critical need for capital, while outlining strategic initiatives in cannabis research and digital assets.

Summary

• WEED, Inc. reported no revenue for the quarter ended June 30, 2026, continuing a trend of operational losses.
• The company has an accumulated deficit of $86,554,873 as of June 30, 2026.
• Cash on hand was a mere $1,066, with a monthly cash burn rate of approximately $2,600.
• Total liabilities increased to $1,443,196, primarily due to increases in accounts payable and accrued officer compensation.
• Management is actively seeking additional capital and exploring new products and services to generate revenue.
• Strategic initiatives include cataloging a proprietary seedbank of cannabis and hemp strains and exploring a digital asset ecosystem with WEEDCoin and BUDZCoin.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued lack of revenue, significant accumulated deficit, and precarious cash position, despite efforts to restructure and explore new technologies.

Positives

• The company is actively pursuing new products and services to generate revenue.
• Strategic partnership with Remergify, Inc. to evaluate a digital asset ecosystem.
• Maintained industrial hemp licenses in Arizona.
• Successfully de-registered non-essential international subsidiaries to simplify corporate structure.
• Possesses a proprietary seedbank of over 250 cannabis and hemp strains, including rare Landrace varieties.

Negatives

• No revenue generated for the period ended June 30, 2026.
• Accumulated deficit of $86,554,873 as of June 30, 2026.
• Cash on hand is only $1,066 as of June 30, 2026.
• Monthly cash burn rate of approximately $2,600.
• Total liabilities increased by $194,929 to $1,443,196 as of June 30, 2026.
• Disclosure controls and procedures were not effective as of June 30, 2026, due to deficiencies including lack of an audit committee and formal processes for related party transactions.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern due to lack of revenues, net losses, and negative working capital.
• The Company is dependent on securing equity and/or debt financing, with no assurance of success.
• The ability to successfully launch digital assets is subject to capital availability and evolving regulatory frameworks.
• Future results may differ materially from forward-looking statements due to inherent risks and uncertainties.
• The company has no audit committee and one individual serves as both CEO and CFO, indicating potential governance weaknesses.

Future Outlook

The company plans to research and enter the hemp and infused beverage industry, conduct its Cannabis Genomic Study, and become a True Seed-to-Sale company providing infrastructure, financial solutions, and real estate options globally. Strategic technology initiatives include the potential launch of WEEDCoin and BUDZCoin, subject to capital and regulatory approvals. The company is actively seeking additional sources of capital to fund operations.

Management Comments

• Management believes its genetic assets represent significant long-term strategic value as the federal regulatory environment for cannabis evolves.
• The Company's ability to successfully launch these digital assets is subject to the availability of capital and the complex, evolving regulatory framework governing digital assets and decentralized finance.
• Management believes it is more likely than not that the net deferred tax assets will not be fully realizable and has provided for a full valuation allowance.

Industry Context

StockSavvy.ai notes that WEED, Inc. operates in the highly regulated and evolving cannabis and biopharmaceutical sectors. The company's focus on genomics, real estate, and potential digital asset integration reflects broader industry trends towards diversification and technological advancement, though its current financial state presents significant challenges to capitalizing on these trends.

Comparison to Industry Standards

• The company's lack of revenue and significant accumulated deficit contrasts sharply with established players in the cannabis industry who have achieved substantial market penetration and profitability.
• Competitors in the biopharmaceutical space, particularly those focused on cannabis-derived compounds, often have significant R&D investment and clinical trial progress, which WEED, Inc. currently lacks due to funding constraints.
• The exploration of digital assets like WEEDCoin and BUDZCoin is a nascent area within the cannabis industry, with few companies having successfully launched such initiatives due to regulatory hurdles and market acceptance challenges.

Corporate Governance

Legal Proceedings

• Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

Related Party Transactions

• Notes payable to related parties totaled $553,603 as of June 30, 2026.
• Nicole M. Breen receives $8,000 per month for services.
• Glenn E. Martin receives $7,000 per month for services.
• Accrued officer compensation was $459,750 as of June 30, 2026.
• The company acquired Hempirical Genetics, LLC from Jeffrey Miller, who became an executive officer.
• Patrick Brodnik signed an executive employee agreement and is considered a related party.

Stakeholder Impact

• Shareholders face continued dilution risk if capital is raised through equity offerings, and the company's going concern status poses significant investment risk.
• Creditors and suppliers may face payment delays given the company's low cash balance and increasing liabilities.
• Employees and consultants may be concerned about the company's financial stability and its ability to meet compensation obligations, especially given accrued officer compensation.

Next Steps

• Continue to pursue new products and services to generate revenue.
• Seek additional sources of capital (equity and/or debt financing).
• Catalog proprietary seedbank genetics for future research and product strategies.
• Evaluate the development of a digital asset ecosystem with Remergify, Inc.
• Continue to maintain and market real estate assets.
• Focus on research and development in the cannabis and hemp sectors.

Key Dates

Recommendation

The company continues to operate without revenue, has a substantial accumulated deficit, and possesses minimal cash reserves, raising significant going concern issues. While strategic initiatives are noted, their success is contingent on substantial future funding, which is not assured. The lack of effective disclosure controls and the absence of an audit committee further heighten the risk profile for investors.

Keywords

cannabis, hemp, biopharmaceutical, real estate, genomics, digital assets, cultivation centers, seedbank